Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery

2026-06-20 · Source: The AI Journal · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Artificial Intelligence & Machine Learning, Health & Medical Research · Depth: Fundamental Awareness, quick

Summary

Greenstone Biosciences, Inc. and Intel Corp. have announced a strategic collaboration to accelerate AI-enabled drug discovery, improve drug safety, and advance precision medicine. This partnership combines Greenstone's large-scale human biobank of induced pluripotent stem cells (iPSC) with Intel's Edge AI advanced computing and AI infrastructure. The goal is to speed up new medicine development by scaling data processing, storage, and analysis using Intel's purpose-built silicon and Greenstone's human genetics and biology. Joseph C. Wu, Greenstone's Co-Founder, highlighted that this collaboration will identify patient-specific response patterns, improve adverse drug effect prediction, and reduce costs. The initiative also supports the growing US FDA regulatory momentum for New Approach Methodologies (NAMs), complementing traditional animal studies and enhancing preclinical testing relevance.

Key takeaway

For Directors of AI/ML in pharmaceutical R&D considering new drug discovery methodologies, this collaboration signals a critical shift towards human-centric approaches. You should evaluate integrating iPSC-based systems with advanced AI computing to enhance preclinical testing, predict adverse drug effects more accurately, and potentially reduce development costs. Prioritize solutions that align with FDA Modernization Act 3.0, leveraging population-scale human cellular models for improved translational relevance in your pipelines.

Key insights

Greenstone and Intel combine human iPSC biology with AI computing to accelerate drug discovery and improve safety.

Principles

• Human-centric drug development is key.
• NAMs enhance preclinical testing relevance.
• AI and iPSC platforms scale drug discovery.

Method

The collaboration integrates Greenstone's iPSC biobank and human genetics with Intel's Edge AI and purpose-built silicon to scale data processing, storage, and analysis for drug development.

In practice

• Identify patient-specific drug response patterns.
• Improve prediction of adverse drug effects.
• Advance new medicines more quickly.

Topics

• AI in Drug Discovery
• Induced Pluripotent Stem Cells
• New Approach Methodologies
• Precision Medicine
• Intel Edge AI
• Pharmaceutical R&D

Best for: AI Scientist, Research Scientist, Director of AI/ML

Related on AIssential

• NVIDIA & Eli Lilly: The AI Revolution in Drug Discovery | Jensen Huang & David Ricks — Co-designing computing stacks for specific problems accelerates applications far beyond Moore's Law.
• Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation — MIDAS, a multimodal GNN, effectively identifies novel immuno-oncology targets by integrating diverse biological data.
• Is AI Drug Discovery Becoming a Data Infrastructure Race? — AI drug discovery's primary bottleneck is the availability of diverse, relevant biological training data, not model architecture or compute.
• Job titles of the future: Nature’s drug designer — Precision drug design, enhanced by AI, can be applied to conservation for targeted ecological health solutions.
• Introducing Perceptic: the AI operating system for drug development — AI can accelerate drug development by connecting multi-modal evidence and decisions across the entire drug lifecycle.
• Demis Hassabis On What AI Will Do Next — AI is evolving into a co-creative partner, poised to accelerate scientific discovery and revolutionize human health within decades.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.